TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19910725

Group type: EXPERIMENTAL
Intervention: Topiramate (TP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 63
Study: 17209695

Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sedentary activity
Number of subjects: 64
Study: 15649655

Group type: EXPERIMENTAL
Intervention: 3 cups (450 mL) of filtered coffee for 3 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 6 cups (900 mL) of filtered coffee for 3 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 1 cup (150 mL) of coffee (single dose)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 2 cups (300 mL) of coffee (single dose)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No coffee (control group for long-term trial)
Number of subjects: 43

Group type: COMPARATOR
Intervention: 0 cups (control group for short-term study)
Number of subjects: 43
Study: 12469330

Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride (colestipol) administered with diltiazem SR
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diltiazem SR alone
Number of subjects: 12
Study: 10341854

Group type: EXPERIMENTAL
Intervention: Interleukin-2 treatment
Number of subjects: 8
Study: 7497581

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propantheline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol or bile salts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study: 1773329

Group type: EXPERIMENTAL
Intervention: Haemonetics Cell Saver
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Solcotrans device
Number of subjects: 12
Study: 7175960

Group type: EXPERIMENTAL
Intervention: Social Skills Training (SST)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combined SST and CR
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nondirective placebo discussion group
Number of subjects: 29
Study: 31775085

Group type: EXPERIMENTAL
Intervention: Emailed radiology alerts (RadAlert system) after educational intervention
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Emailed radiology alerts (RadAlert system) both before and after educational intervention
Number of subjects: 100
Study: 30264364

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation with ablation of the anterior mitral line (after ablation)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (without ablation)
Number of subjects: 41
Study: 28668539

Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet
Number of subjects: 92

Group type: COMPARATOR
Intervention: mNICE diet
Number of subjects: 92
Study: 26459421

Group type: EXPERIMENTAL
Intervention: Intensive BP lowering (systolic BP <120 mm Hg)
Number of subjects: 4331

Group type: COMPARATOR
Intervention: Standard BP lowering (systolic BP <140 mm Hg)
Number of subjects: 4331
Study: 23606340

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study: 21482474

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine (0.5mg/kg, n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Midazolam (5mg, n=12)
Number of subjects: 24
Study: 19854333

Group type: COMPARATOR
Intervention: No counseling (NC)
Number of subjects: 4875

Group type: COMPARATOR
Intervention: 1 counseling session (1C)
Number of subjects: 4875

Group type: COMPARATOR
Intervention: 3 counseling sessions (3C)
Number of subjects: 4875
Study: 17803064

Group type: EXPERIMENTAL
Intervention: HEP1 (human ezrin peptide 324‐337; TEKKRRETVEREKE) monotherapy
Number of subjects: 37
Study: 15298640

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for 4-8 weeks
Number of subjects: 1787
Study: 11104181

Group type: EXPERIMENTAL
Intervention: Exposure with guided threat reappraisal
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Exposure with cognitive load distracter task
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Exposure with both guided threat reappraisal and cognitive load distracter task
Number of subjects: 58

Group type: COMPARATOR
Intervention: Exposure without guided threat reappraisal or cognitive load distracter task
Number of subjects: 58
Study: 8880815

Group type: EXPERIMENTAL
Intervention: Oral transmucosal ketamine (5‐6 mg.kg‐1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intranasal ketamine (5‐6 mg.kg‐1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intramuscular ketamine (5‐6 mg.kg‐1)
Number of subjects: 25
Study: 1440160

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 0
Study: 3930990

Group type: EXPERIMENTAL
Intervention: High dose naloxone (2 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dose naloxone (0.4 mg, approx. 5 micrograms/kg)
Number of subjects: 0
Study: 3663882

Group type: EXPERIMENTAL
Intervention: 4 mg controlled-release (CR) albuterol tablet (q12h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2 mg conventional albuterol tablet (q6h)
Number of subjects: 12
Study: 31665385

Group type: EXPERIMENTAL
Intervention: Daily supplementation with an egg and 150 mL of cow milk for 90 days, and 1 sachet of multiple micronutrient powder for 60 days.
Number of subjects: 472

Group type: COMPARATOR
Intervention: Control group (no nutrition intervention).
Number of subjects: 472
Study: 29311671

Group type: EXPERIMENTAL
Intervention: Home-based exercise training (HET), moderate to high intensity cycling exercise, 3 days/week for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 27220978

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy with intracoronary tirofiban (Group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Aspiration thrombectomy (Group A)
Number of subjects: 150
Study: 26434920

Group type: EXPERIMENTAL
Intervention: 3 months healing time
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 6 months healing time
Number of subjects: 51
Study: 22147646

Group type: EXPERIMENTAL
Intervention: Open Window (art intervention)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 199
Study: 20463260

Group type: EXPERIMENTAL
Intervention: Intervention group (tailored exercise prescription + transtheoretical behavior change counseling)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (exercise prescription alone)
Number of subjects: 360
Study: 18704481

Group type: EXPERIMENTAL
Intervention: Biofeedback training (unilateral EMG biofeedback from the dominant trapezius)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (working with computer mouse more than 50%)
Number of subjects: 164
Study: 16629967

Group type: EXPERIMENTAL
Intervention: Access to bed-chair pressure sensors
Number of subjects: 180
Study: 12701337

Group type: EXPERIMENTAL
Intervention: APAP treatment (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional CPAP treatment (n = 50)
Number of subjects: 100
Study: 10744824

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography during routine upper GI endoscopy
Number of subjects: 32
Study: 9557050

Group type: EXPERIMENTAL
Intervention: Mucosolvan (mucolytic preparation)
Number of subjects: 60
Study: 1304021

Group type: EXPERIMENTAL
Intervention: Spiramycin (1 gram twice daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Erythromycin (500 mg thrice or four times daily)
Number of subjects: 120
Study: 3903239

Group type: EXPERIMENTAL
Intervention: Ribavirin (14 infants)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (12 infants)
Number of subjects: 53
Study: 31419449

Group type: EXPERIMENTAL
Intervention: Moderate-intensity acute aerobic exercise (n=22; 65%-75% HRmax)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-intensity acute aerobic exercise (n=22; ≥ 85% HRmax)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control session (resting)
Number of subjects: 44
Study: 30574757

Group type: EXPERIMENTAL
Intervention: Continuous nursing care including indirect follow‐up, health education, and home visit
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no continuous nursing intervention)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Continuous nursing care
Number of subjects: 80
Study: 27010957

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg every 4 weeks up to week 24
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 91
Study: 24296715

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibition
Number of subjects: 24

Group type: COMPARATOR
Intervention: GLP-1 receptor antagonist (exendin-9)
Number of subjects: 24
Study: 23764140

Group type: EXPERIMENTAL
Intervention: Contextual Cognitive Behavioural Therapy (CCBT)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU) physiotherapy
Number of subjects: 92
Study: 20339479

Group type: EXPERIMENTAL
Intervention: Västerbotten Intervention Programme (VIP)
Number of subjects: 113203
Study: 18430909

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 1002
Study: 16374158

Group type: EXPERIMENTAL
Intervention: Short-stay intensive care (SSIC) treatment (8 hrs of intensive care treatment)
Number of subjects: 600
Study: 12803596

Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 26
Study: 14635284

Group type: EXPERIMENTAL
Intervention: 100 mg twice a day of celecoxib
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: 200 mg twice a day of celecoxib
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: 400 mg twice a day of celecoxib
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: 500 mg twice a day of naproxen
Number of subjects: 1149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1149
Study: 9365356

Group type: EXPERIMENTAL
Intervention: Heavy social drinkers with TBI
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nondrinking subjects with TBI
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heavy social drinkers without TBI
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nondrinking subjects without TBI
Number of subjects: 40
Study: 1395983

Group type: EXPERIMENTAL
Intervention: Intracolonic bypass
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ostomy (Control)
Number of subjects: 22
Study: 3899029

Group type: EXPERIMENTAL
Intervention: Immunotherapy (Levamisole and Intrapleural BCG)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Chemotherapy (CisPlatinum, Adriamycin, and Cytoxan)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy
Number of subjects: 258

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 258
Study: 31515507

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise training (LIRET)
Number of subjects: 33
Study: 29411114

Group type: EXPERIMENTAL
Intervention: Second-generation cryoballoon ablation
Number of subjects: 269

Group type: COMPARATOR
Intervention: Contact-force radiofrequency ablation
Number of subjects: 269
Study: 27871565

Group type: EXPERIMENTAL
Intervention: Fascia iliaca block
Number of subjects: 71

Group type: COMPARATOR
Intervention: Periarticular drug injection
Number of subjects: 71
Study: 24281276

Group type: EXPERIMENTAL
Intervention: 10 mg dronabinol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mg dronabinol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22511794

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion in thyroidectomized patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium bicarbonate infusion in healthy volunteers
Number of subjects: 60
Study: 20122281

Group type: EXPERIMENTAL
Intervention: Supervised, twice weekly exercise training with regular review of airway clearance therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Twice weekly telephone support
Number of subjects: 64
Study: 18772264

Group type: EXPERIMENTAL
Intervention: Nuss technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal chest patients (control group)
Number of subjects: 20
Study: 15753114

Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin on alternate days
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study: 12897285

Group type: COMPARATOR
Intervention: Conventional dose indomethacin (0.2 mg/kg/dose every 12 hours for 3 doses)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Prolonged low-dose indomethacin (0.1 mg/kg/dose daily for 6 doses)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional dose indomethacin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Prolonged low-dose indomethacin
Number of subjects: 140
Study: 10577443

Group type: EXPERIMENTAL
Intervention: Manual compression
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Mechanical clamp
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Pneumatic compression device
Number of subjects: 400
Study: 7594035

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 40099

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 40099

Group type: EXPERIMENTAL
Intervention: Ex-smokers
Number of subjects: 40099
Study: 1851339

Group type: EXPERIMENTAL
Intervention: VACE regimen (vincristine 1.2 mg/m2, doxorubicin 40 mg/m2, cyclophosphamide 700 mg/m2 on day 1 plus etoposide 110 mg/m2 daily for three days)
Number of subjects: 95

Group type: COMPARATOR
Intervention: CVACE regimen (identical to VACE for cycles 3 and 4; cycles 1, 2, 4, and 6 consisted of etoposide 110 mg/m2 for three days plus cisplatin 100 mg/m2 with mannitol diuresis on the second day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: CVACE regimen
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: VACE regimen
Number of subjects: 95
Study: 6119097

Group type: EXPERIMENTAL
Intervention: Cloxazolam (3 mg)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 31550962

Group type: EXPERIMENTAL
Intervention: Low dose aspirin (100 mg daily)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) plus low dose aspirin (40 mg enoxaparin and 100 mg aspirin daily)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) alone (40 mg enoxaparin daily)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 174
Study: 30052964

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 965

Group type: COMPARATOR
Intervention: Myocardial single photon emission computed tomography (SPECT)
Number of subjects: 965

Group type: COMPARATOR
Intervention: SPECT
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 965
Study: 28465004

Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 583

Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 583
Study: 26269685

Group type: EXPERIMENTAL
Intervention: OrVil™ technique
Number of subjects: 84

Group type: COMPARATOR
Intervention: Hemi-double stapling technique (HDST)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 84
Study: 23432037

Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes who reported a higher proportion of their conditions
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Increasing numbers of chronic conditions
Number of subjects: 424

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 424
Study: 22152147

Group type: EXPERIMENTAL
Intervention: Early invitation to food supplementation
Number of subjects: 4436

Group type: EXPERIMENTAL
Intervention: MMS (multiple micronutrient supplementation)
Number of subjects: 4436

Group type: COMPARATOR
Intervention: Usual invitation to food supplementation
Number of subjects: 4436
Study: 18783415

Group type: EXPERIMENTAL
Intervention: Laser-welded titanium frameworks
Number of subjects: 155

Group type: COMPARATOR
Intervention: Gold alloy frameworks
Number of subjects: 155
Study: 17140279

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (exogenous GHB)
Number of subjects: 0
Study: 15136375

Group type: EXPERIMENTAL
Intervention: Comprehensive school‐based asthma program
Number of subjects: 835
Study: 11309635

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg or 120 mg)
Number of subjects: 7478

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7478
Study: 9005911

Group type: EXPERIMENTAL
Intervention: Indomethacin for 14 days
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Indomethacin for 7 days
Number of subjects: 201
Study: 8557525

Group type: EXPERIMENTAL
Intervention: Isoniazid tablets plus pyridoxin tablets once a day for 30 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pyridoxin only
Number of subjects: 20
Study: 2796626

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine, 1 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 352259

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31638448

Group type: EXPERIMENTAL
Intervention: Four Conversations (online and personalized coping and decision aid curriculum)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Wait-listed usual care conditions (control)
Number of subjects: 252
Study: 31176632

Group type: EXPERIMENTAL
Intervention: AP‐CD/LD (50/250 mg, 50/375 mg, or 50/500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AP‐CD/LD
Number of subjects: 0

Group type: COMPARATOR
Intervention: IR‐CD/LD
Number of subjects: 0
Study: 27986606

Group type: EXPERIMENTAL
Intervention: S-ketamine (bolus of 0.11mg/kg, followed by a maintenance infusion of 0.12mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl infusion)
Number of subjects: 28
Study: 25972230

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) including weight loss and physical activity
Number of subjects: 4016

Group type: COMPARATOR
Intervention: Control group: diabetes support and education
Number of subjects: 4016
Study: 24913571

Group type: EXPERIMENTAL
Intervention: Erythropoietin (total dose of about 40,000 U)
Number of subjects: 62
Study: 22386829

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg and Amlodipine 10 mg (T/A)
Number of subjects: 706

Group type: COMPARATOR
Intervention: Amlodipine 10 mg (A)
Number of subjects: 706
Study: 19284397

Group type: EXPERIMENTAL
Intervention: LASER therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Electrotherapy (TENS, stable galvanization)
Number of subjects: 70
Study: 16542638

Group type: EXPERIMENTAL
Intervention: High body checking (scrutinizing bodies in a critical way in the mirror)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low body checking (refraining from body checking and examining bodies in a neutral way)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both high and low body checking
Number of subjects: 60
Study: 14996574

Group type: COMPARATOR
Intervention: Higher neutrophil counts (8.8 +/- 3.8) at 90 minutes for patients with closed infarct-related artery (TIMI grade 0/1 flow)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Percentage of neutrophils (73.2 +/- 10.7% for TMPG 0/1)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Neutrophil counts (8.2 +/- 3.3 for TMPG 0/1)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Higher neutrophil counts
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Greater percentage of neutrophils
Number of subjects: 394
Study: 12052284

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 9066353

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid/serum ratios for soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Serum levels for soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Single periventricular gadolinium-enhancing lesion (n = 16)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhancing lesions detected
Number of subjects: 46
Study: 8410217

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (very high doses) administered within 8 hours of injury
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed treatment with methylprednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone administration
Number of subjects: 0
Study: 3108851

Group type: EXPERIMENTAL
Intervention: Rivanol-induced interruption of pregnancy (non-invasive)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Invasive interruption of pregnancy (control)
Number of subjects: 550
Study: 31199549

Group type: EXPERIMENTAL
Intervention: Active BreEStim
Number of subjects: 10
Study: 29474510

Group type: EXPERIMENTAL
Intervention: Worksite cafeteria 2.0 intervention (nudging and social marketing strategies)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard worksite cafeteria practices)
Number of subjects: 30
Study: 26319959

Group type: EXPERIMENTAL
Intervention: Pride condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joy condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 24735200

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 80
Study: 22500386

Group type: EXPERIMENTAL
Intervention: Qinggan Huatan Huoxue Recipe (QHHR)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Danning Tablet
Number of subjects: 150
Study: 20573778

Group type: EXPERIMENTAL
Intervention: Thiazide-like diuretic (indapamide 1.5 mg SR) + ACE inhibitor (perindopril 2-4 mg)
Number of subjects: 3845

Group type: COMPARATOR
Intervention: Placebo (matching placebo for indapamide and perindopril)
Number of subjects: 3845
Study: 17646516

Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine 2 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine 4 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine 7 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine 10 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine 14 mg
Number of subjects: 60